News and Trends 17 May 2023 Diagnosing inflammatory diseases with synthetic peptides Common inflammatory disorders such as ulcerative colitis and Crohn’s disease can be diagnosed or monitored by measuring the protein calprotectin in stool samples, while serum levels of calprotectin could be used to monitor the inflammation status in rheumatoid arthritis. Calprotectin concentrations in patient samples are typically determined using antibodies that bind and detect the protein, […] May 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 5 Apr 2023 Antimicrobial peptides: a promising class to tackle antimicrobial resistance The discovery of penicillin in 1928 by Alexander Fleming was a momentous moment in the world of healthcare, eventually leading to the development of antibiotic drugs that allowed physicians to treat illnesses and infections that were once severe and life-threatening. But our reliance on antibiotics has now led to an emerging global health problem in […] April 5, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2023 Ablaze Pharmaceuticals to develop first-in-class therapy for liver cancer in China Ablaze Pharmaceuticals, a biotech company focused on developing targeted radiotherapy (TRT) to benefit cancer patients in China, is developing plans for a first-in-class novel peptide drug candidate against GPC3. The proprietary GPC3-targeting peptide is being licensed from RayzeBio. Upon in-license of product candidates by Ablaze from RayzeBio, Ablaze will be responsible for clinical development and […] March 31, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Mar 2023 Iktos raises €15.5M to expand AI drug discovery technologies Iktos, a company specializing in artificial intelligence (AI) for new drug discovery, has closed a €15.5 million ($16.4 million) Series A financing co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital. This financing will enable Iktos to further develop its AI and drug discovery capabilities and expand its existing SaaS software […] March 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2023 Korean researchers develop antimicrobial peptides discovery tool Antimicrobial peptides (AMPs) are a promising new weapon for combating the growing antimicrobial resistance (AMR) of bacteria and other harmful microorganisms. Now, researchers from the Gwangju Institute of Science and Technology (GIST) in South Korea have developed a new, easy-to-interpret AI-powered AMP prediction model. The tool, named AMP-BERT, can capture the functional and structural properties […] February 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2023 Cytovation melanoma study under way Cytovation ASA, a Norwegian clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy, announces that the first patient has been dosed in its phase 2a study. The trial is investigating CyPep-1 monotherapy in patients with advanced melanoma refractory to checkpoint inhibitors (CPIs). The study is an expansion arm […] February 16, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2023 IMV presents positive lymphoma trial results IMV Inc. has announced positive preliminary data from its VITALIZE phase 2B trial. The study is evaluating IMV Inc. lead DPX product, maveropepimut-S (MVP-S), in combination with pembrolizumab, in patients with relapsed, refractory diffuse large B cell lymphoma (r/r DLBCL). IMV Inc. is a biopharmaceutical company developing a portfolio of immune-educating therapies based on its […] February 14, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Feb 2023 New method to design new peptide therapeutics Researchers at Hokkaido University in Japan have developed a novel method to design and develop peptide antibiotics in large numbers, which could prove critical to controlling antibiotic resistance. Applications of new molecules as drugs are expected to be effective in treating diseases that are difficult to cure with currently used conventional drugs. Peptides are one […] February 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Feb 2023 Orbit Discovery and Endevica Bio to develop cachexia therapeutics Orbit Discovery Limited has entered into a multi target research agreement with Endevica Bio Inc. Endevica creates first-in-class therapeutics for cachexia caused by cancer and other chronic conditions. Its lead compound has proven to be safe and well-tolerated in phase 1 trials. The collaboration aims to accelerate Endevica’s development of advanced G-protein coupled receptor (GPCR)-targeting […] February 2, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2023 New tool to fight antibiotic resistance The World Health Organization (WHO) ranks antibiotic resistance as one of the top 10 threats to global health. In response, researchers at Chalmers University of Technology in Sweden have developed a new spray that can kill antibiotic-resistant bacteria, and that can be used for wound care and directly on implants and other medical devices. “Our […] January 26, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2023 Orbit Discovery and SanegeneBio collaborate to identify targeting peptides for RNAi drugs Orbit Discovery Limited has entered into a master service agreement with SanegeneBio Inc., a start-up company dedicated to developing novel RNAi-based medicines. The focus of the collaboration is to identify tissue-specific delivery of a wide range of RNA therapeutics to efficiently knock down disease-causing genes. The agreement covers activities ranging from hit ID to cell-based […] January 6, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022 Funding to develop wearable patch for type 2 diabetes A project to develop a patch worn on the cheek that delivers peptide treatments for type 2 diabetes has been awarded just under €3.8 million ($3.9 million) by the EU’s Horizon Europe RESILIENCE program. The ‘BUCCAL-PEP’ project will combine skills to develop a multifunctional biomaterial patch which allows, for the first time, delivery of peptide […] November 23, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email